A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Of The Efficacy And Safety Of The Rotigotine Transdermal Patch In Chinese Subjects With Early-stage Idiopathic Parkinson's Disease
Phase of Trial: Phase III
Latest Information Update: 01 Jul 2016
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors UCB Pharma Inc
- 18 Jun 2015 Results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
- 14 Jun 2015 Primary endpoint: Mean change from baseline to EoM UPDRS II and III has been met.
- 10 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.